Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 7:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 180 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cerebral Atrophy Clear all
Completed Phase 2 Interventional Results available

A Study of TAK-341 in Treatment of Multiple System Atrophy

NCT05526391
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Placebo, TAK-341
Drug
Lead sponsor
Takeda
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Farmington Hills, Michigan • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 7, 2026, 7:44 AM EDT
Enrolling by invitation No phase listed Observational

North American Prodromal Synucleinopathy Consortium

NCT03623672
View directory record Official record
Conditions
REM Sleep Behavior Disorder, Parkinson Disease, Lewy Body Disease, Dementia With Lewy Bodies, Multiple System Atrophy, REM Sleep Parasomnias
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Sun City, Arizona • Los Angeles, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Jun 7, 2026, 7:44 AM EDT
Recruiting Not applicable Interventional

Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension Symptoms

NCT04782830
View directory record Official record
Conditions
Orthostatic; Hypotension, Neurogenic, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Orthostatic; Hypotension, Parkinsonism
Interventions
Accelerometer, placebo pill, Midodrine or atomoxetine pill
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jun 7, 2026, 7:44 AM EDT
Completed No phase listed Observational

A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years

NCT01847287
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2013 · Synced Jun 7, 2026, 7:44 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

BRINK (BRain In Kidney Disease) Memory Study 2.0

NCT04975464
View directory record Official record
Conditions
Chronic Kidney Diseases, Dementia, Dementia, Vascular, Stroke, Alzheimer Disease, Cognitive Decline, Cognitive Impairment, Cognitive Dysfunction, Kidney Diseases, Diabetes, Cerebral Atrophy, Small Vessel Ischemic Disease
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
50 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 7, 2026, 7:44 AM EDT
Completed Not applicable Interventional Results available

Nebivolol in the Supine Hypertension of Autonomic Failure

NCT01044693
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
Placebo, Nebivolol 5 mg, metoprolol tartrate 50 mg, Sildenafil25 mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Jun 7, 2026, 7:44 AM EDT
Recruiting Not applicable Interventional

CPAP for the Treatment of Supine Hypertension

NCT05489575
View directory record Official record
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Supine Hypertension, Neurogenic Orthostatic Hypotension
Interventions
Active CPAP, Sham CPAP, Sleeping in a head-up tilt (HUT) position
Device · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jun 7, 2026, 7:44 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

NCT06445465
View directory record Official record
Conditions
Alpha-Synucleinopathy, Parkinson's Disease, Dementia With Lewy Bodies, Multisystem Atrophy
Interventions
[18F]MNI-1216
Drug
Lead sponsor
Invicro
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jun 7, 2026, 7:44 AM EDT
Completed No phase listed Observational

Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate

NCT02307877
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Jun 7, 2026, 7:44 AM EDT
Completed Phase 1Phase 2 Interventional

Automated Abdominal Binder for Orthostatic Hypotension

NCT03482297
View directory record Official record
Conditions
Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
Interventions
automated abdominal binder, Sham binder, Placebo, Midodrine
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 7, 2026, 7:44 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Lu AF82422 in Participants With Multiple System Atrophy

NCT05104476
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Lu AF82422, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
40 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
16
States / cities
Fountain Valley, California • La Jolla, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 7, 2026, 7:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease

NCT01155492
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jun 7, 2026, 7:44 AM EDT
Completed Not applicable Interventional

A Randomized Exercise Trial for Wheelchair Users

NCT00866112
View directory record Official record
Conditions
Spinal Cord Injury, Multiple Sclerosis, Muscular Dystrophy, Cerebral Palsy, Spina Bifida, Amputation, Arthritis, Stroke
Interventions
Educational session to promote physical activity, Minimal contact
Other
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lawrence, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Jun 7, 2026, 7:44 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study

NCT06273150
View directory record Official record
Conditions
Dentatorubral-Pallidoluysian Atrophy
Interventions
Positive genetic test for pathological expansion in ATN1
Other
Lead sponsor
University College, London
Other
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jun 7, 2026, 7:44 AM EDT
Completed No phase listed Observational

Teriflunomide Tecfidera LMCE

NCT03526224
View directory record Official record
Conditions
Tecfidera, Teriflunomide
Interventions
Dimethyl Fumarate, Teriflunomide
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jun 7, 2026, 7:44 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

NuroSleeve Powered Brace & Stimulation System to Restore Arm Function

NCT04798378
View directory record Official record
Conditions
Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies, Arthrogryposis, Spinal Cord Injuries, Charcot-Marie-Tooth, Stroke, Weakness of Extremities as Sequela of Stroke, Weakness Due to Upper Motor Neuron Dysfunction, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Arm Paralysis, Cerebral Palsy
Interventions
Neurosleeve
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Wilmington, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Jun 7, 2026, 7:44 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy

NCT05167721
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
Autologous Mesenchymal Stem Cells, Placebo
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 7, 2026, 7:44 AM EDT
Available No phase listed Expanded access

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

NCT07238062
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 85 Years
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 7, 2026, 7:44 AM EDT
Enrolling by invitation Not applicable Interventional

Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device

NCT07222605
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration, Posterior Cortical Atrophy (PCA), Neurological Diseases or Conditions, Dementia
Interventions
MemorEM
Device
Lead sponsor
eQ8Health Corporation d/b/a CareONE Concierge
Industry
Eligibility
45 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jun 7, 2026, 7:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic and Family Studies of Inherited Muscle Diseases

NCT00001331
View directory record Official record
Conditions
Dermatomyositis, Glycogen Storage Disease Type II, Glycogen Storage Disease Type VII, Myositis, Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Jun 7, 2026, 7:44 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism

NCT03446807
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
Interventions
Droxidopa, Placebo Oral Tablet
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jun 7, 2026, 7:44 AM EDT
Withdrawn Phase 1 Interventional

The Role of Endothelin in the Supine Hypertension of Autonomic Failure

NCT01119417
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure, Multiple System Atrophy
Interventions
BQ123, Saline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Jun 7, 2026, 7:44 AM EDT
Completed Not applicable Interventional

Effects of Standing on Non-Ambulatory Children With Neuromuscular Conditions

NCT02428673
View directory record Official record
Conditions
Osteopenia, Spinal Muscular Atrophy, Cerebral Palsy, Muscular Dystrophy, Spina Bifida, Rett Syndrome
Interventions
Assisted Standing Treatment Program
Other
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
3 Years to 14 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jun 7, 2026, 7:44 AM EDT
Active, not recruiting No phase listed Observational

Clinical Laboratory Evaluation of Chronic Autonomic Failure

NCT03648905
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
Interventions
13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB), 18F-Dopamine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 7, 2026, 7:44 AM EDT